Decoding the Hype and Fear of Nanomedicines - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Decoding the Hype and Fear of Nanomedicines
Does nanotechnology offer a cure-all or a kill all? We speak with Ruth Duncan about the real potential of nanomedicines.


Pharmaceutical Technology Europe
Volume 24, Issue 2

Q: It has been claimed that many Big Pharma companies are losing interest in nano-enabled drugs. Do you agree with this statement?

Have they ever been very interested?

This statement is not true given my understanding of the term "nanomedicine". It is always dangerous to make generalisations such as overhyping a field at the outset and then over condemning it later on.

Certainly, parenteral drug-targeting strategies have never been an easy fix and scientific experts in this area have always known that. There are too many claims of 'platform technologies' that able to deliver any drug candidate, but this is naive because every system needs to be optimised on a case-by-case basis.

Many basic science publications claim that new technologies—not only nanotechnology—are not practical for translation/industrial development. This can be because of:

  • difficulty in achieving reproducible quality
  • safety issues regarding the dose and route of administration
  • lack of enhanced efficacy
  • issues regarding scale-up potential or cost/practicality for clinical use.

However, if you look at the drug attrition rate for candidates that have entered clinical trials, I don't believe that nano-enabled systems have fared any worse than traditional low-molecular chemical entities. I think more data in this area would be beneficial.

Q: How are regulators addressing nanotechnology?

The development and routine use of nanomedicines is not new. Regulators review each new technology on its own merit and make an integrated assessment of quality, safety and efficacy to understand whether the risk–benefit profile is acceptable. This will continue to happen for all medicines, nano or otherwise.

With the advent of novel nanomaterials and the growing interest in complex, multicomponent nanomedicines, regulatory agencies continue to review all specific/emerging needs in this field. Both the FDA and the EMA have established specific teams to address nanomedicines at both national and international levels.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here